MARC record from Internet Archive

LEADER: 08654cam 2200781 a 4500
001 ocm28346238
003 OCoLC
005 20210731000742.0
008 930617s1992 gw a b 101 0 eng
040 $aNLM$beng$cNLM$dEET$dIPL$dAGL$dBAKER$dCGC$dYDXCP$dZWZ$dGEBAY$dBDX$dOCLCF$dDEBBG$dOCLCQ$dOCLCO$dOCLCQ$dOCLCO$dOCLCA$dNLM$dOCLCO$dOCLCA
016 7 $a9310911$2DNLM
019 $a26060016
020 $a9783887630164
020 $a3887630165
035 $a(OCoLC)28346238$z(OCoLC)26060016
050 4 $aRS3$b.I5 1991
060 00 $aQV 4$bI571t 1991
070 0 $aRS201.A2C66$b1991
072 0 $aX380
082 04 $a615.1$bIn75p, 1991
084 $aVR 3089$2rvk
111 2 $aInternational Congress of Pharmaceutical Sciences of F.I.P$n(51st :$d1991 :$cWashington, D.C.)
245 10 $aTopics in pharmaceutical sciences 1991 :$bproceedings of the 51st International Congress of Pharmaceutical Sciences of F.I.P., held in Washington D.C., U.S.A., 1-6 September 1991 /$cedited by D.J.A. Crommelin, K.K. Midha.
260 $aStuttgart :$bMedpharm Scientific Publishers,$c©1992.
300 $a672 pages :$billustrations
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
500 $a"International Pharmaceutical Federation, Fédération Internationale Pharmaceutique (F.I.P.), the Hague."
504 $aIncludes bibliographical references and indexes.
505 00 $tPeptide and Protein Delivery --$g1.$tPharmaceutical proteins and peptides: a contemporary perspective /$rD. T. Liu --$g2.$tChemical and physical stability of protein pharmaceuticals /$rC. Oliyai, C. Schoneich, G. S. Wilson and R. T. Borchardt --$g3.$tChemical modification and disposition of proteins and peptides: biopharmaceutical aspects /$rH. Sezaki, Y. Takakura and M. Hashida --$g4.$tDrug carrier systems for proteins and peptides /$rR. Couvreur, J. C. Gautier, J. L. Grangier, G. Pastor, F. Puisieux, C. Damge and C. Michel --$tTrends in Intranasal and Pulmonary Delivery of Drugs --$g5.$tNasal delivery of peptides, factors affecting nasal absorption /$rL. Illum --$g6.$tTherapeutic possibilities for nasal delivery /$rT. Nagai and Y. Suzuki --$g7.$tPhysico-chemical principles in aerosol delivery /$rI. Gonda --$tUpdate Lecture --$g8.$tTrends in transdermal drug delivery /$rM. A. Gonzalez --$tStatus of Absorption Enhancers --$g9.$tMechanisms of action of absorption enhancers /$rS. Muranishi and M. Murakami --$g10.$tEnhanced transdermal delivery of testosterone using the Theraderm[actual symbols not reproducible] TDS /$rN. A. Mazer --$g11.$tAbsorption enhancement in nasal drug delivery /$rJ. Verhoef, W. A. J. J. Hermens, N. G. M. Schipper, S. G. Romeijin and F. W. H. M. Merkus --$g12.$tPermeability enhancers for oral dosing: efficacy and potential toxicity /$rW. Curatolo and E. S. Swenson --$tCritical Issues in the Use and Standardization of Pharmaceutical Excipients
505 80 $g13.$tInternational harmonization of compendial standards for pharmaceutical excipients /$rR. E. Shangraw --$g14.$tEvaluation of drug-excipient interactions in solid dosage forms /$rE. B. Vadas --$g15.$tCurrent considerations in the choice of anti-microbial preservatives for liquid and semi-solid dosage forms /$rM. Iwatsuru and T. Sonobe --$g16.$tA rational approach to the drying of labile biologicals: the role of salts and stabilizers /$rF. Franks and C. Van Den Berg --$tBioavailability, Bioequivalence World Standards --$g17.$tPharmacodynamic considerations in bioavailability and bioequivalence assessments /$rG. Levy --$g18.$tEuropean initiatives in standards for harmonization of bioavailability and bioavailability/bioequivalence requirements /$rU. Gundert-Remy --$g19.$tBioavailability and bioequivalence criteria in Japan /$rH. Ogata --$g20.$tNorth American initiatives in bioavailability/bioequivalence assessment /$rI. J. McGilveray and E. Ormsby --$tImmunoessays in Drug Monitoring --$g21.$tNew approaches in immunoassay techniques /$rC. E. Cook --$g22.$tDevelopment and use of immunoassays for neuroleptic drug monitoring /$rG. McKay, S. R. Marder, T. Van Putten, E. M. Hawes, J. W. Hubbard and K. K. Midha --$g23.$tComparison of immunoassay techniques for measurement of therapeutic drugs /$rJ. F. Wilson --$tFundamental and Regulatory Aspects of Drug Chirality --$g24.$tStereoselective drug action and disposition: fundamental and clinical aspects /$rB. Testa --$g25.$tFDA perspective on the manufacturing and control of chiral drugs /$rW. H. De Camp
505 80 $g26.$tMobile phase additives as probes of solute binding to protein based high-performance liquid chromatographic chiral stationary phases /$rT. A. G. Noctor and I. W. Wainer --$tPharmacoepidemiology: A Global Perspective --$g27.$tPharmacoepidemiology: the European approach /$rH. G. Leufkens --$g28.$tPharmacoepidemiology: an attempt to stimulate projects in Asia /$rG. Tomson, U. Bergman and V. K. Diwan --$g29.$tThe potential for pharmacoepidemiology in Central and South America /$rD. Lee --$g30.$tThe use of automated databases in North America /$rD. J. Blackburn --$tAIDS: An Update --$g31.$tAIDS: a global perspective /$rJ. M. Mann --$tPopulation Pharmacokinetics in Clinical Trials --$g32.$tConcepts and definitions associated with population pharmacokinetics /$rT. M. Ludden --$g33.$tPopulation pharmacokinetics: methodological concerns in applications /$rA. Iliadis --$g34.$tEstimation of population pharmacokinetic parameters in Japanese patients /$rM. Yasuhara, Y. Tanigawara and R. Hori --$tUpdate Lecture --$g35.$tGenetic polymorphism in drug metabolism and its role in patient medication /$rM. Eichelbaum, A. S. Gross and H. K. Kroemer --$tReactive and Active Phase II Metabolites --$g36.$tReactive and active metabolites from the glutathione pathway /$rP. J. Van Bladeren --$g37.$tActive and reactive phase-II metabolites: the glucuronides pathway /$rH. Spahn-Langguth and L. Z. Benet --$g38.$tThe sulfation pathway /$rC. D. Klaassen and Z. Gregus
505 80 $g39.$tThe pharmaco- and toxicokinetics of reactive and active phase II metabolites /$rL. Z. Benet, A. Bischer, C. Volland and H. Spahn-Langguth --$tReceptor Effector Coupling --$g40.$tThe calcium channel: structure, function and therapeutic implications /$rD. J. Triggle --$g41.$tRegulation of hormone and transmitter sensitive adenylyl cyclase /$rA. Bar-Sinai, I. Marbach and A. Levitzki --$g42.$tSignal transduction by G-proteins /$rM. Schimerlik --$g43.$tCoupling of pharmacological receptors to polyphosphoinositide turnover /$rJ. H. Wojcikiewicz, N. T. Burford and S. R. Nahorski --$tMedicinal Plants with Anticancer Activity --$g44.$tMethods for the discovery of antitumor agents in plants /$rM. Suffness --$g45.$tDiscovery of new antitumor agents from Asian medicinal plants /$rH. Itokawa --$g46.$tIsolation and structure elucidation of antitumor agents from South American plants /$rM. Silva and M. Bittner --$g47.$tPlant immunostimulants for cancer therapy /$rH. Wagner.
650 0 $aPharmaceutical chemistry$vCongresses.
650 0 $aPharmacy$vCongresses.
650 0 $aDrugs$vCongresses.
650 0 $aPharmacology$vCongresses.
650 7 $aPréparations pharmaceutiques$xCongrès comme sujet.$2fmesh
650 7 $aPharmacologie$xCongrès comme sujet.$2fmesh
650 7 $aChimie pharmaceutique$xCongrès comme sujet.$2fmesh
650 7 $aDrugs.$2fast$0(OCoLC)fst00898761
650 7 $aPharmaceutical chemistry.$2fast$0(OCoLC)fst01060115
650 7 $aPharmacology.$2fast$0(OCoLC)fst01060259
650 7 $aPharmacy.$2fast$0(OCoLC)fst01060285
650 7 $aPharmakologie$2gnd
650 7 $aPharmazie$2gnd
650 7 $aKongress$2gnd
650 2 $aPharmacology.
655 4 $aKongress$zWashington (DC)$y1991.
655 4 $aKongreß$zWashington (DC)$y1991.
655 7 $aConference papers and proceedings.$2fast$0(OCoLC)fst01423772
655 2 $aCongress.
700 1 $aCrommelin, D. J. A.$q(Daan J. A.)
700 1 $aMidha, K. K.
856 41 $3Table of contents$uhttp://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002897461&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
938 $aBaker & Taylor$bBKTY$c143.00$d143.00$i3887630165$n0002080965$sactive
938 $aBrodart$bBROD$n02012014$c$135.95
938 $aYBP Library Services$bYANK$n1255547
029 0 $aNLM$b9310911
029 1 $aAU@$b000009193032
029 1 $aAU@$b000045178150
029 1 $aDEBBG$bBV004715528
029 1 $aGEBAY$b1635728
029 1 $aNZ1$b3757802
029 1 $aZWZ$b014279746
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 33 OTHER HOLDINGS